Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026
Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026
Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Fineline Cube Aug 10, 2026
Company Deals Digital

Shenzhen NeuroPlus Secures Seed Funding for Neuromodulation and Bioelectronic Medicine

Fineline Cube Sep 22, 2022

Shenzhen NeuroPlus has reportedly raised “tens of millions” of renminbi in a seed financing round...

Company

Merck KGaA Opens Viral Clearance Lab in Shanghai’s Biologics Testing Center

Fineline Cube Sep 22, 2022

German pharmaceutical giant Merck KGaA has opened a viral clearance (VC) laboratory as part of...

Company Deals

METiS Therapeutics In-Licenses Voronoi’s Pan-RAF Inhibitor Program

Fineline Cube Sep 22, 2022

Cambridge, Massachusetts-based METiS Therapeutics has unveiled its first in-license deal, signing with South Korea’s Voronoi...

Policy / Regulatory

Heilongjiang Launches ‘Longjiang Huiminbao’ Supplementary Health Insurance Scheme

Fineline Cube Sep 22, 2022

Heilongjiang province has launched its first provincial-level supplementary commercial health insurance scheme, branded “Longjiang Huiminbao.”...

Company Deals

Immuno Cure BioTech Acquires Majority Stake in Shanghai Teresa Healthcare

Fineline Cube Sep 21, 2022

Hong Kong-based Immuno Cure BioTech has announced the acquisition of a controlling 92.6% stake in...

Company Drug

Lepu Biotechnology’s MRG003 Receives Orphan Drug Designation from FDA

Fineline Cube Sep 21, 2022

China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received orphan drug...

Company Deals

Kamari Pharma Completes $8M Investment from Chinese Fund GIBF2

Fineline Cube Sep 21, 2022

Israel-based Kamari Pharma has announced the completion of an $8 million investment from the Chinese...

Company Drug

Joincare’s Modified Drug XYP-001 Gains NMPA Approval for IPF Trial

Fineline Cube Sep 21, 2022

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...

Company Deals

Koutech Robotics Secures Series A Funding for Surgical Innovation

Fineline Cube Sep 21, 2022

China-based Koutech Robotics (Shanghai) Co., Ltd, a leading ultra-micro, high-precision surgical robot platform company, has...

Company Drug

CARsgen Therapeutics Presents Positive Phase Ib/II Data for CT053 at CAR-TCR Summit

Fineline Cube Sep 21, 2022

China-based CARsgen Therapeutics Holdings Ltd presented the results of a multi-center, open-label Phase Ib/II study...

Company Deals

Joincare Pharmaceuticals Prices GDRs on SIX Swiss Exchange

Fineline Cube Sep 21, 2022

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has priced its Global Depository Receipts...

Company

Northeast Pharmaceutical to Invest in Shanghai Subsidiary for ADC and CAR-T Development

Fineline Cube Sep 21, 2022

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced plans to invest RMB 500 million...

Policy / Regulatory

Beijing Designates 923 Medical Entities for National Reimbursement Drug List

Fineline Cube Sep 21, 2022

The Beijing Municipal Medical Insurance Bureau has released a notification indicating that a total of...

Company

Lee’s Pharmaceutical Reports H1 Revenue Growth Amid Product Portfolio Shift

Fineline Cube Sep 20, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its H1 2022 interim financial report,...

Company Drug

Junshi Biosciences’ Tuoyi Approved for First-Line NSCLC Treatment in China

Fineline Cube Sep 20, 2022

China’s Center for Drug Evaluation (CDE) has approved Junshi Biosciences’ (HKG: 1877, SHA: 688180) Tuoyi...

Company Drug

Sun-Novo’s STC007 Gains NMPA Approval for Postoperative Pain Study

Fineline Cube Sep 20, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd has announced that it has received approval from...

Company Deals

WuXi Biologics Partners with Elpiscience for Macromolecule Development

Fineline Cube Sep 20, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple...

Company Drug

Tasly Pharmaceuticals Gains NMPA Approval for B1344 Diabetes Study

Fineline Cube Sep 20, 2022

China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National...

Company Drug

Clover Biopharmaceuticals Reports Positive Phase III Data for COVID-19 Vaccine SCB-2019

Fineline Cube Sep 20, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced additional positive Phase III clinical trial data...

Company Drug

RemeGen Announces Positive Phase III Results for Telitacicept in SLE

Fineline Cube Sep 20, 2022

China-based pharma firm RemeGen (HKG: 9995) has announced the conclusion of a Phase III confirmatory...

Posts pagination

1 … 662 663 664 … 705

Recent updates

  • GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled
  • Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor
  • WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation
  • Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials
  • Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Legal / IP

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.